CA3007311A1 - Composition de conjugues d'agonistes-constructions d'anticorps et leurs procedes d'utilisation - Google Patents

Composition de conjugues d'agonistes-constructions d'anticorps et leurs procedes d'utilisation Download PDF

Info

Publication number
CA3007311A1
CA3007311A1 CA3007311A CA3007311A CA3007311A1 CA 3007311 A1 CA3007311 A1 CA 3007311A1 CA 3007311 A CA3007311 A CA 3007311A CA 3007311 A CA3007311 A CA 3007311A CA 3007311 A1 CA3007311 A1 CA 3007311A1
Authority
CA
Canada
Prior art keywords
compound
antibody
conjugate
salt
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3007311A
Other languages
English (en)
Inventor
Peter Armstrong Thompson
Badreddin EDRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opi Vi - Ip Holdco LLC
Original Assignee
Opi Vi - Ip Holdco LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/173,075 external-priority patent/US20170158772A1/en
Application filed by Opi Vi - Ip Holdco LLC filed Critical Opi Vi - Ip Holdco LLC
Publication of CA3007311A1 publication Critical patent/CA3007311A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne diverses compositions de constructions d'anticorps. L'invention concerne aussi des compositions de conjugués de composés immunostimulateurs-constructions d'anticorps. L'invention concerne également des procédés de préparation et d'utilisation des conjugués de composés immunostimulateurs-constructions d'anticorps. Les procédés incluent des procédés de traitement d'affections comme le cancer. L'invention concerne par ailleurs un genre de composés agonistes du stimulateur STING et un procédé de synthèse.
CA3007311A 2015-12-07 2016-12-07 Composition de conjugues d'agonistes-constructions d'anticorps et leurs procedes d'utilisation Abandoned CA3007311A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562264260P 2015-12-07 2015-12-07
US62/264,260 2015-12-07
US15/173,075 2016-06-03
US15/173,075 US20170158772A1 (en) 2015-12-07 2016-06-03 Compositions of antibody construct - agonist conjugates and methods of use thereof
US201662371141P 2016-08-04 2016-08-04
US62/371,141 2016-08-04
PCT/US2016/065353 WO2017100305A2 (fr) 2015-12-07 2016-12-07 Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA3007311A1 true CA3007311A1 (fr) 2017-06-15

Family

ID=59013332

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3007311A Abandoned CA3007311A1 (fr) 2015-12-07 2016-12-07 Composition de conjugues d'agonistes-constructions d'anticorps et leurs procedes d'utilisation

Country Status (4)

Country Link
EP (1) EP3386536A4 (fr)
CA (1) CA3007311A1 (fr)
DE (1) DE212016000029U1 (fr)
WO (1) WO2017100305A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
SG10202008647TA (en) 2016-10-04 2020-10-29 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018144955A1 (fr) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Compositions de produit de recombinaison-peptide et leurs méthodes d'utilisation
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2018208667A1 (fr) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Composés dinucléotidiques cycliques en tant qu'agonistes sting
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
WO2019027858A1 (fr) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Agonistes benzo[b]thiophène de sting pour le traitement du cancer
CN107365361B (zh) * 2017-08-21 2020-05-19 中国药科大学 与pd-l1结合的重复域锚定蛋白及其用途
WO2019046500A1 (fr) * 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Dinucléotides cycliques utilisés en tant qu'agents anticancéreux
KR102651946B1 (ko) * 2017-08-31 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019051489A1 (fr) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
BR112020009126A2 (pt) 2017-11-10 2020-10-20 Takeda Pharmaceutical Company Limited compostos do modulador sting e métodos de fabricação e uso
WO2019125974A1 (fr) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Composés dinucléotidiques cycliques utilisés comme agonistes sting
EP3505188A1 (fr) 2017-12-29 2019-07-03 Invivogen Conjugués de dinucléotide pro-cycliques pour l'induction de la cytokine
JP7326319B2 (ja) 2018-04-03 2023-08-15 メルク・シャープ・アンド・ドーム・エルエルシー Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
WO2019195063A1 (fr) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting
CA3101368A1 (fr) 2018-05-25 2019-11-28 Incyte Corporation Composes heterocycliques tricycliques en tant qu'activateurs de sting
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
CN112714649B (zh) 2018-09-06 2024-07-02 第一三共株式会社 环状二核苷酸衍生物及其抗体药物偶联物
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020190725A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
AU2020267486A1 (en) 2019-05-09 2021-11-11 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as STING modulators
AU2020286523A1 (en) * 2019-06-03 2022-02-03 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
EP3980057A1 (fr) 2019-06-04 2022-04-13 Institut Curie Méthodes de production de monomères et d'oligomères de la sous-unité b de la toxine de shiga (stxb), et leurs utilisations
TW202116358A (zh) 2019-07-19 2021-05-01 美商免疫感應治療公司 抗體-干擾素基因刺激蛋白(sting)促效劑結合物及其於免疫療法之用途
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
US20220313835A1 (en) * 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
WO2021110987A1 (fr) 2019-12-06 2021-06-10 Life & Soft Procédés et appareils permettant de diagnostiquer un cancer à partir d'acides nucléiques acellulaires
CN111233850B (zh) * 2020-01-21 2022-09-23 南开大学 含苯并噻唑氨基和杂芳基的萘酚衍生物与制备方法和用途
EP4106819A1 (fr) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Conjugués d'anticorps de nectine-4 et leurs utilisations
CN115209921A (zh) 2020-03-06 2022-10-18 第一三共株式会社 包含新型环状二核苷酸衍生物的抗体药物偶联物
EP4117790A1 (fr) 2020-03-13 2023-01-18 Hephaistos-Pharma Lipopolysaccharides (lps) détoxifiées, lps naturellement non toxiques, et leurs utilisations
CA3178464A1 (fr) 2020-05-15 2021-11-18 Immunesensor Therapeutics, Inc. Polytherapies a agoniste de sting assorties d'inhibiteurs de points de controle immunitaires
CA3183993A1 (fr) 2020-07-01 2022-01-06 Peter R. Baum Conjugues d'anticorps anti-asgr1 et leurs utilisations
EP3943505A1 (fr) 2020-07-22 2022-01-26 Encefa Peptides cd31 de liaison à cd38 et leurs utilisations
JPWO2022050300A1 (fr) 2020-09-02 2022-03-10
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
EP4255475A1 (fr) 2020-12-02 2023-10-11 Institut Curie Protéines de sous-unité b de toxine de shiga (stxb) pfonctionnalisées et leurs conjugués
EP4297874A1 (fr) 2021-02-26 2024-01-03 Brenus Pharma Cellules cancéreuses soumises à de multiples stress non autologues et leurs utilisations pour vacciner contre des cancers et traiter des cancers
AU2022315305A1 (en) 2021-07-23 2024-02-01 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
CA3231944A1 (fr) 2021-09-16 2023-03-23 Carole GUILLONNEAU Domaines de liaison anti-cd45rc humaine et leurs utilisations
WO2023109942A1 (fr) * 2021-12-17 2023-06-22 Jacobio Pharmaceuticals Co., Ltd. Constructions lieurs-composés comprenant de nouveaux composés utiles en tant qu'agonistes de sting et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101038A0 (en) * 1991-02-21 1992-11-15 Gilead Sciences Inc Agent specific for trombin and its use
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
RU2737765C2 (ru) * 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US10548985B2 (en) * 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors

Also Published As

Publication number Publication date
EP3386536A4 (fr) 2019-07-31
DE212016000029U1 (de) 2017-07-30
WO2017100305A3 (fr) 2017-07-20
EP3386536A2 (fr) 2018-10-17
WO2017100305A2 (fr) 2017-06-15
WO2017100305A8 (fr) 2017-09-08

Similar Documents

Publication Publication Date Title
US20210139604A1 (en) Compositions of antibody construct-agonist conjugates and methods of use thereof
CA3007311A1 (fr) Composition de conjugues d'agonistes-constructions d'anticorps et leurs procedes d'utilisation
US20190336615A1 (en) Tumor targeting conjugates and methods of use thereof
AU2018236272B2 (en) Benzazepine compounds, conjugates, and uses thereof
CA3049842A1 (fr) Compositions de produit de recombinaison-peptide et leurs methodes d'utilisation
WO2019084060A1 (fr) Conjugués et leurs procédés d'utilisation pour l'administration sélective d'agents immunomodulateurs
WO2018227023A1 (fr) Conjugués de construction d'anticorps
CA3065852A1 (fr) Conjugues d'anticorps constitues de composes immunomodulateurs et leurs utilisations
US20210154317A1 (en) Compositions and methods for the treatment of viral infections
CA3111784A1 (fr) Compositions pour le traitement d'une maladie avec des conjugues immunostimulants
IL271760B (en) Antibody-drug conjugates and methods for their preparation
WO2020056194A1 (fr) Composés de benzazépine, conjugués et utilisations associées
CA3111580A1 (fr) Conjugues d'anticorps d'agonistes de recepteurs de type toll
AU2020358726A1 (en) Combination therapy with immune stimulatory conjugates
GB2552041A (en) Compositions of antibody construct-agonist conjugates and methods thereof
RU2780334C2 (ru) Бензазепиновые соединения, конъюгаты и их применение

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220607

FZDE Discontinued

Effective date: 20220607